YOKOGAWA/SENSIRE
6.6.2019 08:02:06 CEST | Business Wire | Press release
Yokogawa Electric Corporation (TOKYO:6841) and Finland-based Sensire Ltd. announce that they have reached an agreement for Yokogawa to take a €6 million stake in Sensire and to begin collaborating in the cold chain monitoring field. Through this initiative, both companies aim to develop and provide new services that combine Yokogawa’s Industrial Internet of Things (IIoT) architecture, subscription-based IIoT services being developed by its amnimo Inc. subsidiary, and Sensire’s cold chain temperature monitoring solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190605005285/en/
Demand for solutions that facilitate the temperature-controlled transportation of perishable items from the point of origin to the point of consumption is on the rise, and this need is particularly acute with pharmaceutical and food products that require strict temperature control.
Sensire Ltd. offers a full range of specialized temperature monitoring solutions mainly for the cold chain. Sensire’s compact and power efficient temperature sensors collect and transmit temperature data to the cloud for access from PCs and mobile devices. Supporting a range of wireless communication protocols suitable for land, sea, and air transport applications, Sensire’s solutions ensure access to continuous real-time monitoring data that delivers vital quality and compliance information when and where it is needed.
Yokogawa is developing a cloud-based IIoT architecture in collaboration with Microsoft Corporation of the United States, and based on this is starting to provide solutions for the remote monitoring of physical quantities. In addition, Yokogawa’s amnimo Inc. business unit is developing IIoT services that use this architecture to provide access to data from not only manufacturing plants but also many other types of facilities and situations, with the aim of delivering subscription-based Measurement as a Service (MaaS).
Having taken a 35.2% stake in Sensire, Yokogawa is now this company’s largest shareholder. Utilizing Yokogawa’s know-how and global network, the two companies will work together to develop new temperature monitoring solutions for the cold chain and other logistics services, and expand this business.
Tsuyoshi Abe, a Yokogawa senior vice president and head of the company’s Marketing Headquarters, commented, “Under its Transformation 2020 mid-term business plan, Yokogawa is now exploring new business models such as recurring revenue while also aiming to expand its business in the pharmaceutical and food fields. I am convinced that Sensire’s solutions will accelerate these efforts, and I trust that we will be able to deliver new value to applications where precise temperature control is critical by combining the technologies of both companies.”
JP Asikainen, founder and CEO of Sensire, added, “I believe that this collaboration with Yokogawa will provide us an opportunity to expand the business globally and ensure the transition to the next-generation of cloud architecture. We look forward to making the latest and best cold chain solutions available to customers in a broader range of industries and applications.”
Related links
amnimo
Inc
.
About Yokogawa
Founded in 1915, Yokogawa engages in
broad-ranging activities in the areas of measurement, control, and
information. The industrial automation business provides vital products,
services, and solutions to a diverse range of process industries
including oil, chemicals, natural gas, power, iron and steel, and pulp
and paper. With the life innovation business, the company aims to
radically improve productivity across the pharmaceutical and food
industry value chains. The test & measurement, aviation, and other
businesses continue to provide essential instruments and equipment with
industry-leading precision and reliability. Yokogawa co-innovates with
its customers through a global network of 113 companies spanning 60
countries, generating US$3.6 billion in sales in FY2018. For more
information, please visit www.yokogawa.com
.
About Sensire
Sensire Ltd., founded in 2007 by CEO JP
Asikainen, offers comprehensive wireless and automatic real-time
monitoring products that serve the globally vital climate-controlled
chain. The IoT tech company’s solutions help deliver better safety and
quality in various cold chain operations from food industry applications
to pharmaceutical logistics, as well as in many climate-sensitive
healthcare premises. Sensire is committed to being the leading innovator
in cold chain IoT technology in order to offer best-in-class products
and services to its customers. Headquartered in Joensuu, Finland, the
company turnover in FY2018 was EUR 1.5 million. For more information,
visit www.sensire.com
The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation, Sensire Ltd., or their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190605005285/en/
Contact:
Yokogawa Electric Corporation Philip Lewis Public Relations Manager Email: Yokogawa-pr@cs.jp.yokogawa.com 2-9-32 Nakacho Musashino-shi Tokyo Japan 180-8750 Tel: +81 422-52-5530
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
Unpack ’26 sommerrejsetrends: Flere vælger indenlandske rejser, når de tænker mere bevidst over deres rejsevalg21.5.2026 12:35:00 CEST | Pressemeddelelse
Rejsebranchens førende databrevne trendrapport lancerer sin første sommerudgave nogensinde – Unpack ’26 Summer: The Trends in Travel I dag har Hotels.com udgivet Unpack ’26 Summer: The Trends in Travel, den nyeste udgave af virksomhedens førende trendrapport i rejsebranchen, som viser, hvordan rejseadfærd former sommerens rejsevalg. Efterspørgslen på indenlandske rejser præger sommerens ferieplanlægning. Interessen på sociale medier for indenlandske ferier er globalt steget med 77% sammenlignet med sidste år, og 44% af danske rejsende planlægger en indenlandsk rejse denne sommer*. Fra store sportsbegivenheder og koncerter til rejser inspireret af film og tv bygger Unpack ’26 Summer på indsigter fra den årlige hovedrapport Unpack ’26: The Trends in Travel™ for at fremhæve, hvor rejsende tager hen denne sommer. HHver tendens bygger på førstehåndsdata fra Hotels.com® kombineret med indsigter fra rejsende og overvågning af sociale medier. “Denne sommer bliver der stadig rejst – men på nye
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
